ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.

What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
News
Media Releases
Long Term Analytical Validation Study Further Confirms BluePrint as a Reliable Genomic Profiling Assay for Early Stage Breast Cancer Patients
PRESS RELEASE ย IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ MARCH 31, 2020 โ Agendia, Inc., a world leader in precision oncology for breast cancer, announced today that Translational Cancer published long term analytical performance Read More
Agendia COVID-19 Statement
As a valued customer we wanted to reach out and assure you that we are monitoring the situation regarding the outbreak of Corona Virus Disease (COVID-19) very closely; your patientโs sample and the safety of Read More
Results from the IMPACt Trial Show Agendia Assays Consistently Inform Treatment Planning and Increase Physician Confidence when Caring for Patients with Early Stage Breast Cancer
PRESS RELEASE Laura van โt Veer, PhD, Co-Inventor of MammaPrint, Honored with the PMWC Luminary Award at Precision Medicine World Conference 2020 ย IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ February 13, 2020 โ Agendia, Read More
Laura van โt Veer, PhD, Co-Inventor of MammaPrint, Honored with the PMWC Luminary Award at Precision Medicine World Conference 2020
PRESS RELEASE Laura van โt Veer, PhD, Co-Inventor of MammaPrint, Honored with the PMWC Luminary Award at Precision Medicine World Conference 2020 ย IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ 17 January 2020 โ Laura Read More